NCT01518998

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 420 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Fimasartan , Amlodipine, Placebo	Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination

Timeline

• Start date: 2011-08-01
• Primary completion: 2013-10-01
• Completion: 2013-11-01
• First posted: 2012-01-26
• Last updated: 2016-07-01

Locations

1 site across 1 country: South Korea